Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Professor Dr Hans-Georg Rammensee Awarded the Bayer Hansen Family Award 2013

Published: Friday, March 08, 2013
Last Updated: Friday, March 08, 2013
Bookmark and Share
Prestigious Hansen Family Award recognizes Hans-Georg Rammensee’s pioneering scientific research activities.

immatics biotechnologies GmbH has announced that the Company’s scientific inspirer and co-founder Professor Dr Hans-Georg Rammensee has been awarded the Hansen Family Award 2013 for his contribution to the advancement of cancer immunotherapy.

Hans-Georg Rammensee received his award at a ceremony in Berlin last night.

The Hansen Family Award was established in 2000 by Professor Kurt Hansen, former chairman of Bayer’s Management and Supervisory Board, to recognize medical achievements in German-speaking countries.

The award, which carries a prize money of 75.000 EUR, is presented every two years in alternation with the Otto Bayer Award and acknowledges innovative research in areas related to medical science and medicine.

This year the Hansen Family Award recognizes the contribution of Hans-Georg Rammensee to the field of immunology and particularly its translation into patient treatment as recently published in Nature Medicine by immatics, the University of Tuebingen and co-workers.

Hans-Georg Rammensee is Head of immatics’ Scientific Advisory Board and co-founder of the Company. He is currently Head of the Department of Immunology at the University of Tuebingen.

His work on major histocompatibility complex (MHC) molecules, which play a vital role in immune responses, and associated peptides is considered a cornerstone in the history of immunology.

He has authored more than 250 papers, many thereof published in journals like Nature and Science, and has co-edited several journals including Immunogenetics, Cellular and Molecular Life Science and European Journal of Immunology.

He has received numerous well known scientific awards for his work, e.g. the Gottfried Wilhelm Leibniz Prize 1992, the Robert Koch Prize 1993, and the Paul Ehrlich and Ludwig Darmstaedter Prize 1996.

Dr Harpreet Singh, Chief Scientific Officer of immatics, said: “We are delighted that Hans-Georg has been recognized again for his pioneering contribution to immunology which has formed the basis of immatics’ innovative approach to developing therapeutic cancer vaccines. immatics has made significant progress with its lead vaccine IMA901 for advanced kidney cancer - progress that would have not been possible without the groundbreaking work by Hans-Georg.”

Professor Dr Hans-Georg Rammensee said: “I am thrilled to have received this award as the representative of a highly skilled and motivated team of researchers over the years. I am also very happy to see the progress that immatics has made in advancing its multi-peptide cancer vaccine IMA901 for the treatment of renal cancer patients. We have seen very encouraging results with this vaccine in the phase 2 trial making us believe that this approach has the potential to change the treatment of renal cancer, and most likely of other cancers as well, significantly.”

“Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival,” Walter S., Weinschenk T. et al. (2012) Nature Medicine. Published online: 29 July 2012.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

immatics and BioNTech to Advance a Novel Class of Fully Personalized Therapeutic Cancer Vaccines
Regulatory authority approves clinical trial for Glioma Actively Personalized Vaccine Consortium (GAPVAC).
Thursday, October 16, 2014
immatics Receives €22 Million Final Tranche of Series D Fundraising
Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics’ Human Immunopeptidome Program to identify the most relevant targets for cancer immunotherapies.
Thursday, July 17, 2014
Immatics to Continue Work on Vaccine (IMA950) for Glioblastoma
A new cancer vaccine (IMA950) for glioblastoma has met the two primary endpoints of safety and immunogenicity in a trial conducted by Cancer Research UK.
Thursday, April 24, 2014
immatics Closes €34 Million Financing
immatics’ lead cancer vaccine IMA901 to report interim phase 3 data in 2014 and final data in 2015.
Tuesday, October 15, 2013
immatics Presents Encouraging Overall Survival Data from a Phase 2 Study in CRC
T-cell responses to the IMA910 colorectal cancer vaccine peptides show a clear correlation with longer overall survival.
Monday, June 04, 2012
immatics Wins 2012 TiE50 Award
immatics chosen as a leading company in the life sciences category by the world's largest entrepreneurial network.
Friday, May 25, 2012
immatics Appoints Dr Rainer Kramer as CBO
Dr. Kramer will lead immatics’ business development unit.
Thursday, April 12, 2012
immatics Presents Positive Phase II Results with IMA910 in CRC Patients
Study shows a consistent association between immune response to IMA910 and all clinical endpoints and an excellent tolerability profile.
Wednesday, January 25, 2012
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Micro Disease-Detecting Senor Created
Researchers at McMaster University have created a microscopic disease-detecting sensor that can turn on to detect trace amounts of substances.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Understanding Treatment Resistant Melanoma
Researchers have determined how advanced melanoma becomes resistant; a development toward developing treatments.
Investigating ‘Black Box’ of Human Genetics
Investigations into inactive X chromosomes have shown unusual DNA repeat elements are essential for maintaining 3D structure.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!